

The civil society **monitoring of progress** in hepatitis C response for PWID related to the WHO 2030 elimination goals in 35 European countries



Prof. Mojca Maticic, MD, PhD

University Medical Centre Ljubljana
Faculty of Medicine, University of Ljubljana
Slovenia

INHSU Conference : 13-15 October, 2021

Disclosure



Within the last 36 months:

- Lecturer: Abbvie, Bayer, Merck, Sandoz
- Manuscript preparation: Abbvie, Gilead, Merck
- Travel/accommodational meeting expences: Abbvie, Gilead, Merck

No conflict of interest regarding this presentation


WHO strategy towards elimination of viral hepatitis as a public health threat

GOALS




Hepatitis B and C new infections and mortality by WHO regions, 2019


Global progress report
on HIV, viral hepatitis
and sexually transmitted
infections, 2021



Accountability for the global health
sector strategies 2016–2021: actions
for impact




The progress achieved under global health sector strategies, 2016-2021



- Information
- Interventions
- Equity
- Financing
- Innovation

One of first areas to reach SDG targets for 2020 but huge gaps in diagnosis remain


Major increase in hepatitis C treatment affecting mortality but need to rapidly accelerate hepatitis B and C diagnosis



HCV, Europe, 2016 - 2019:

- **33%** of known HCV infected received DAA treatment between 2015-2019
- **only 24%** HCV infected have been diagnosed
- the coverage **needs to increase** because the scale-up of diagnostics and treatment **has been slow**


The progress achieved under global health sector strategies, 2016-2021



- Information
- Interventions
- Equity
- Financing
- Innovation

One of first areas to reach SDG targets for 2020 but huge gaps in diagnosis remain

Major increase in hepatitis C treatment affecting mortality but need to rapidly accelerate hepatitis B and C diagnosis




3.3 Delivering for equity

The most marginalized, vulnerable and underserved populations, who face the highest rates of infection, often have the poorest access to services. Persistent stigma, inequalities, criminalization, violence and other sociostructural barriers are preventing response efforts from reaching the people and communities who need them most.

The road to elimination is complex

A continuum-of-care



Boston consulting group. https://image-src.bcg.com/Images/BCG-Road-to-Elimination_tcm104-166034.pdf

Marcias J, et al. *J Hepatol* 2019; 71: 45-51. Iversen J, et al *J Hepatol* 2019; 70: 33-9.

Platt L, et al. *The Cochrane Database of Systematic Reviews* 2016; 2017: CD012021.

Monitoring response to WHO HCV elimination goals



ECDC (2020). *Monitoring the responses to hepatitis B and C epidemics in EU/EEA Member States, 2019*. Stockholm: ECDC; 2020.


EMCDDA (2019). *Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe: the elimination barometer, Technical Reports, Publications Office of the European Union, Luxembourg; 2019*.

Palayew A, et al. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. *PLoS ONE* 2020;15(7): e0235715.

Tammi T, Rigoni R, Matičič M, Schäffer D, van der Gouwe D, Schiffer K, et al. *Civil Society Monitoring of Harm Reduction in Europe, 2019. Data Report*. Amsterdam. Correlation – European Harm Reduction Network; 2020.

Monitoring HCV response for PWID in Europe: Correlation – European Harm Reduction Network

2019



Maticic et al. *Harm Reduct J* (2020) 17:89
<https://doi.org/10.1186/s12954-020-00439-3>

Harm Reduction Journal

RESEARCH

Open Access

The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries



M. Maticic^{1,2*}, Z. Pirnat², A. Leicht³, R. Zimmermann⁴, T. Windelinck⁵, M. Jauffret-Roustide⁶, E. Duffell⁷, T. Tammi⁸ and E. Schatz⁹

Tammi T, Rigoni R, Matičič M, Schäffer D, van der Gouwe D, Schiffer K, et al. *Civil Society Monitoring of Harm Reduction in Europe, 2019. Data Report*. Amsterdam. Correlation – European Harm Reduction Network; 2020.

Matičič M, et al. *Harm Reduct J* 2020;17(1):89.




METHODS (in 2019)

- A cross-sectional prospective survey
- Respondents: HR CSOs = Focal points of C-EHRN

35 FP from 35 countries


- A 27-item on-line questionnaire
- Q from 4 strategic fields:
 - Use/impact of guidelines on HCV testing/treatment for PWID
 - Availability/functioning of a continuum-of-care
 - Changes compared to previous year
 - The role of CSOs of PWID
- Q asked for the year 2018

RESPONDENTS: Harm reduction CSOs from 35 European countries Focal points of C-EHRN




RESULTS:

Reported use of most relevant guidelines for HCV treatment and indications for treatment in different groups of PWID from 35 European countries (2019)




RESULTS:

Improvements in a continuum-of-care compared to the previous year and the role of harm reduction CSOs and NGOs of PWID reported from 35 European countries (2019).



Monitoring HCV response for PWID in Europe: Correlation – European Harm Reduction Network



2020



Location of C-EHRN Focal points, 2020



Rigoni, R, Tammi, T, van der Gouwe, D, Oberzil, V,; Csak R, Schatz, E. (2021) *Civil Society Monitoring of Harm Reduction in Europe, 2020. Executive Summary.* Amsterdam, Correlation – European Harm Reduction Network.

A survey: Comparing the progress in response to WHO hepatitis C elimination goals for PWID in 35 European countries between 2019 and 2020



A survey: METHODS




- Included: HR CSOs = Focal points of C-EHRN

35 Focal points from 34 countries

- **Comparing responses from the C-EHRN Reports 2019 and 2020**
- Q from 4 strategic fields:
 - Use/impact of guidelines on HCV testing/treatment for PWID
 - Availability/functioning of a continuum-of-care
 - Changes compared to previous year
 - The role of CSOs of PWID

Proportion of countries responding to HCV testing&treatment **policy** in the years 2019 and 2020 N=35



Proportion of countries responding to HCV testing&treatment **policy** in the years 2019 and 2020 N=35


Figure 22: Do you think these guidelines impact accessibility to testing and HCV treatment of people who inject drugs (PWID) in your city?

HCV treatment

Positive impact
accessibility to

No HCV treatment

No HC




2020

2019

120


Proportion of countries performing **HCV confirmatory testing for PWID** at various settings in the years 2019 and 2020

N=35




Where can HCV-infected PWID perform a non-invasive diagnostic examination for the **evaluation of liver fibrosis** (ie Fibroscan®) ?

2020




Proportion of countries performing **HCV treatment** for PWID at various settings in the years 2019 and 2020


N=35




Proportion of countries performing HCV **testing and treatment** at various settings in the years 2019 and 2020, as reported from 35 European countries



Increasing the role of HR CSOs and NGOs of PWID compared to a previous year



Compared to the previous year, regarding HCV, did the coordination between health-care providers (GPs, clinics) and social service providers (NGOs, HR services) change?



CONCLUSION

- According to the CSO reports PWID are still in an unequal position and often deprived from proper HCV interventions
- The overall picture in the report 2020 has not changed much from that of 2019
- There is still a lot to be developed in the continuum-of-care and integration of HCV testing and treatment on site is still too rarely the case
- CSOs engagement in HCV awareness, testing and treatment for PWID remains high, however major shortfalls in provision of those services remain
- CSOs must be included in strategic planning for HCV continuum-of-care and monitoring progress towards elimination goals

Acknowledgement

C-EHRN HCV STUDY GROUP

Leicht A¹, Zimmermann R², Windelinckx T³, Jauffret-Roustide M⁴, Duffell E⁵, Tammi T⁶, Schatz E⁷

¹Fixpunkt e. V., Berlin, Germany, ²Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany, ³Free Clinic, Antwerp, Belgium, ⁴Cermes3 (Inserm U988/CNRS 8211/EHESS/Université de Paris), Paris, France, ⁵European Centre for Disease Prevention and Control, Stockholm, Sweden, ⁶Finnish Institute for Health and Welfare, Helsinki, Finland, ⁷Correlation-European Harm Reduction Network, Amsterdam, The Netherlands

C-EHRN FOCAL POINTS

Country	City	Organization	Country	City	Organization
Albania	Tirana	Aksion Plus	Luxembourg	Luxembourg	Jugend - an Drogenh�llef
Austria	Vienna	Suchthilfe Wien gGmbH	Netherlands	Amsterdam	Mainline Foundation
Belgium	Antwerp	vzw Free Clinic	Norway	Kristiansand	proLAR Nett
Croatia	Rijeka	NGO for helping people with drug use disorders "Vida"	Poland	Krakow	MONAR – Krakow
Cyprus	Nicosia	Cyprus National Addictions Authority	Portugal	Vila Nova de Gaia	Ag�ncia Piaget Para o Desenvolvimento
Czech Republic	Prague	SANANIM	North Macedonia	Skopje	HOPS - Healthy Option Project Skopje
Denmark	Copenhagen	Health Team for the Homeless	Romania	Bucharest	CARUSEL
Estonia	Tallinn	NGO Convictus Estonia	Russia	St. Petersburg/ Amsterdam	Charitable Fund "Humanitarian Action"/ AFEW
Finland	Helsinki	EHYT Ry/ A-Clinic Foundation	Scotland	Glasgow	Scottish Drugs Forum
France	Paris	F�d�ration Addiction	Serbia	Novi Sad	Prevent
Georgia	Tbilisi	Georgian Harm Reduction Network	Slovakia	Bratislava	Odyseus
Germany	Berlin	Deutsche Aidshilfe	Slovenia	Ljubljana	Association Stigma
Greece	Athens-Salonika	Positive Voice	Spain	Barcelona	Red Cross Catalonia
Hungary	Budapest	Rights Reporter Foundation	Sweden	Stockholm	Stockholm Drug Users Union
Ireland	Dublin	Ana Liffey Drug Project	Switzerland	Bern	Infodrog
Italy	Milan/ Rome	Fondazione LILA Milano Italian League for Fighting AIDS/ Forum Droghe	Ukraine	Kiev	ICF "AIDS Foundation East-West" (AFEW-Ukraine)
Lithuania	Vilnius	Coalition "I Can Live"	United Kingdom	London	Release

THANK YOU !